Reality Check

MMIT Reality Check on Non-Small Cell Lung Cancer Systemic Therapy (August 2022)

A review of market access for non-small cell lung cancer systemic therapy treatments shows that under the pharmacy benefit, about 38% of the lives under commercial formularies are covered with utilization management restrictions. Around 38% of the lives under Medicare formularies are not covered for at least one of the drugs.

0 Comments

MMIT Reality Check on Ulcerative Colitis (August 2022)

A review of market access for ulcerative colitis treatments shows that under the pharmacy benefit, about 64% of the lives under commercial formularies are covered with utilization management restrictions. Around 34% of the lives under Medicare formularies are not covered for at least one of the drugs.

0 Comments

MMIT Reality Check on Duchenne Muscular Dystrophy (August 2022)

A review of market access for Duchenne muscular dystrophy treatments shows that under the pharmacy benefit, about 39% of the lives under commercial formularies are covered with utilization management restrictions. Around 28% of the lives under health exchange formularies are not covered for at least one of the drugs.

0 Comments

MMIT Reality Check on Parkinson’s Disease (August 2022)

A review of market access for Parkinson’s disease treatments shows that under the pharmacy benefit, about 37% of the lives under commercial formularies are covered with utilization management restrictions. Around 40% of the lives under Medicare formularies are not covered for at least one of the drugs.

0 Comments

MMIT Reality Check on Kidney Cancer (August 2022)

A review of market access for kidney cancer treatments shows that under the pharmacy benefit, about 52% of the lives under commercial formularies are covered with utilization management restrictions. Around 25% of the lives under Medicare formularies are not covered for at least one of the drugs.

0 Comments

MMIT Reality Check on Bipolar Disorder (July 2022)

A review of market access for bipolar disorder treatments shows that under the pharmacy benefit, about 24% of the lives under commercial formularies are covered with utilization management restrictions. Around 19% of the lives under Medicare formularies are not covered for at least one of the drugs.

0 Comments

MMIT Reality Check on Psoriatic Arthritis (July 2022)

A review of market access for psoriatic arthritis treatments shows that under the pharmacy benefit, about 73% of the lives under commercial formularies are covered with utilization management restrictions. Around 37% of the lives under Medicare formularies are not covered for at least one of the drugs.

0 Comments

MMIT Reality Check on Acute Lymphoblastic Leukemia (July 2022)

A review of market access for acute lymphoblastic leukemia treatments shows that under the pharmacy benefit, about 37% of the lives under commercial formularies are covered with utilization management restrictions. Around 42% of the lives under Medicare formularies are not covered for at least one of the drugs.

0 Comments

MMIT Reality Check on Hemophilia A or B With Inhibitors (July 2022)

A review of market access for hemophilia A or B with inhibitors treatments shows that under the pharmacy benefit, about 42% of the lives under commercial formularies are covered with utilization management restrictions. Around 16% of the lives under health exchange formularies are not covered for at least one of the drugs.

0 Comments

MMIT Reality Check on Type 2 Diabetes (SGLT2 and Combo) (2Q2022)

A review of market access for type 2 diabetes (SGLT2 and combo) treatments shows that under the pharmacy benefit, about 43% of the lives under commercial formularies are covered with utilization management restrictions. Around 20% of the lives under Medicare formularies are not covered for at least one of the drugs.

0 Comments